Unassociated Document
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2014

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
     
     
Delaware
000-52120
56-2590442
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
     
     
465 Route 17 South, Ramsey, New Jersey
  
07446
(Address of principal executive offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552

 
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
ITEM 5.07        
Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders (the "Annual Meeting") of ADMA Biologics, Inc. (the "Company) held on June 19, 2014, the holders of the Company’s common stock voted to elect each of the following Class I directors to serve for a term of three years, until his successor is duly elected and qualified:

Director
  
Votes For
  
Votes Withheld
  
Broker Non-Votes
Dov A. Goldstein, M.D.
  
6,728,971
  
0
  
838,309
Bryant E. Fong
  
6,728,971
  
0
  
838,309
 
At the Annual Meeting, the Company's stockholders also voted on the following proposals:
 
Proposal
  
For
  
Against
  
Abstain
  
Broker Non-Votes
To approve the Company's 2014 Omnibus Incentive Compensation Plan
  
6,235,338
  
492,133
  
1,500
  
838,309
To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2014
  
7,567,280
  
0
  
0
  
N/A
 
 
 
 
 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

June 20, 2014
ADMA Biologics, Inc.
   
   
 
By:
/s/ Brian Lenz
   
Name:
Brian Lenz
   
Title:
Chief Financial Officer